Throughout the last three months, 8 analysts have evaluated Boston Scientific BSX, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $63.0, a high estimate of $66.00, and a low estimate of $60.00. Surpassing the previous average price target of $60.62, the current average has increased by 3.93%.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Boston Scientific among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Marie Thibault | BTIG | Maintains | Buy | $64.00 | $64.00 |
| Larry Biegelsen | Wells Fargo | Maintains | Overweight | $62.00 | $62.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $66.00 | $59.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $62.00 | $59.00 |
| Joshua Jennings | TD Cowen | Raises | Outperform | $65.00 | $58.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $61.00 | $58.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $64.00 | $60.00 |
| Mike Matson | Needham | Lowers | Buy | $60.00 | $65.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Boston Scientific's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Boston Scientific's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
Delving into Boston Scientific's Background
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Boston Scientific: A Financial Overview
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 11.26% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin is impressive, surpassing industry averages. With a net margin of 14.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Boston Scientific's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.72%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.49%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
What Are Analyst Ratings?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
